Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19492456 | 0.94 | CTNNB1 (0.38) | CTNNB1WNT3ASTING1 | |
| SCHEMBL22221997 | 0.89 | CTNNB1 (0.38) | CTNNB1WNT3ASTING1 | |
| SCHEMBL22221839 | 0.80 | CTNNB1 (0.43) | CTNNB1WNT3ASTING1 | |
| SCHEMBL20662320 | 0.75 | NISCH (0.32) | NPC1RAB9A | |
| SCHEMBL19312347 | 0.75 | LTA4H (0.47) | NPC1RAB9A | |
| SCHEMBL19492439 | 0.70 | FAAH (0.32) | — | |
| SCHEMBL18839045 | 0.69 | LTA4H (0.46) | CTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL21966458 | 0.68 | LTA4H (0.34) | NPC1RAB9A | |
| SCHEMBL19155331 | 0.68 | FAAH (0.31) | — | |
| SCHEMBL19301936 | 0.67 | NPC1 (0.31) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457672-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190055227-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055227-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CTNNB1 6/4885WNT3A 4/4885STING1 1440/4885 |
| US-10457672-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | CTNNB1 5/4885WNT3A 4/4885STING1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.